<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005630</url>
  </required_header>
  <id_info>
    <org_study_id>99-028</org_study_id>
    <secondary_id>CDR0000067783</secondary_id>
    <secondary_id>NCI-G00-1775</secondary_id>
    <nct_id>NCT00005630</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>Vaccination of Non-Small Cell Lung Cancer Patients Against Mutated K-Ras: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
      Colony-stimulating factors such as sargramostim may increase the number of immune cells found&#xD;
      in bone marrow or peripheral blood.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy and sargramostim in&#xD;
      treating patients who have non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether a specific T-cell response can be induced in patients with stage IB-IV&#xD;
           non-small cell lung cancer treated with mutant K-ras peptide vaccine (limited to the&#xD;
           specific K-ras peptide mutation in their tumors) and sargramostim (GM-CSF).&#xD;
&#xD;
        -  Determine whether skin test reactivity or HLA type correlates with the induction of&#xD;
           anti-K-ras immune responses in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive sargramostim (GM-CSF) intradermally (ID) on days 1-10 beginning a&#xD;
      maximum of 6 months after complete surgical resection. Patients receive mutant K-ras peptide&#xD;
      vaccine (limited to the specific K-ras mutation in their tumors) ID on day 7. Treatment&#xD;
      repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed at 4 and 12 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ras peptide cancer vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven stage IB-IV non-small cell lung cancer&#xD;
&#xD;
               -  Non-squamous cell histology only&#xD;
&#xD;
               -  Must have undergone curative surgery within the past 6 months and must be free of&#xD;
                  recurrence&#xD;
&#xD;
               -  Tumor must demonstrate a specific K-ras mutation at codon 12 for which a vaccine&#xD;
                  preparation is available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 17&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent medical condition that would preclude compliance or immunologic response&#xD;
             to study treatment&#xD;
&#xD;
          -  No other serious concurrent medical condition&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer or&#xD;
             carcinoma in situ of the uterine cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior postoperative chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent systemic steroids&#xD;
&#xD;
          -  Concurrent inhaled steroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to spleen&#xD;
&#xD;
          -  At least 3 weeks since prior postoperative radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs or antiinflammatory drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee M. Krug, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>September 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

